“Dr. Braun is a respected clinician, researcher, and professor with extensive knowledge about the pathology of IBD and other critical conditions. We are extremely fortunate to have him as new addition to uBiome’s Scientific Advisory Board.” - Dr. Jessica Richman, PhD, co-founder and CEO
SAN FRANCISCO (PRWEB) October 25, 2018
uBiome, the leader in microbial genomics, announces the addition of Dr. Jonathan Braun, MD, PhD, Chair of the Department of Pathology and Laboratory Medicine at University of California Los Angeles (UCLA), to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Braun will bring to uBiome a deep expertise on the role of the immune system in resistance and susceptibility to inflammatory bowel disease and cancer. The appointment will help uBiome continue its advancement in human microbiome research.
“Dr. Braun is a respected clinician, researcher, and professor with extensive knowledge about the pathology of IBD and other critical conditions,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are extremely fortunate to have him as new addition to uBiome’s Scientific Advisory Board.”
Dr. Braun serves as a Professor of Pathology and Laboratory Medicine at the David Geffen School of Medicine at UCLA and as the chair of the Department of Pathology and Laboratory Medicine. Previously, Dr. Braun served as the chairman of the National Scientific Advisory Board of the Crohn's and Colitis Foundation, president of both the Clinical Immunology Society and the Federation of Clinical Immunology Societies (FOCIS), and on the editorial boards of Gastroenterology, Inflammatory Bowel Diseases, and Clinical Immunology. He has published more than 75 primary research studies, 14 issued patents, and co-founded three biopharma companies.
About joining uBiome's Scientific Advisory Board, Dr. Braun said, “As a GI investigator, I am keenly aware of the diverse impact of the microbiomes of the body on health. As a pathologist, I am motivated by the need to develop robust and accessible strategies to monitor the microbiome across time, personal activities, and intentional interventions. uBiome is a leader in developing and disseminating such strategies and thereby advancing both the science and its adoption by the broader community.”
In addition to Dr. Braun, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.